Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 542 participants.
Also called NCT04724837
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 542 participants
- Sponsor
- Registry
-
NCT04724837 -
2020-004101-32
-
- Other papers using this trial's data
- Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, Denmark, Georgia, Hungary, Italy, Japan, Malaysia, Netherlands, Poland, Slovakia, South Africa, Spain, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT04724837. Randomized; triple masking; primary purpose treatment. Start 2021-04-28 (actual); primary completion 2023-06-01 (actual). Results posted on 2024-07-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
- Acronym
- ZENITH-CKD
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Zibotentan
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct04724837- Content hash
09f4082dfa0fbdf9cdeffd39860c80f45e9ebad41923fd403a57a57124d4299e